Regenerative Medical Technology (RMTG) Cash & Equivalents (2017 - 2026)

Regenerative Medical Technology's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 13.2% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 13.2% YoY), while the FY2025 annual figure was $956718.0, down 17.94% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.1 million, up from $956718.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $2.5 million in Q1 2022, with the low at $530540.0 in Q4 2023.
• The 5-year median for Cash & Equivalents is $1.2 million (2025), against an average of $1.3 million.
• Peak annual rise in Cash & Equivalents reached 212.44% in 2022, while the deepest fall reached 83.51% in 2022.
• Regenerative Medical Technology's Cash & Equivalents stood at $1.6 million in 2022, then tumbled by 67.75% to $530540.0 in 2023, then soared by 119.74% to $1.2 million in 2024, then decreased by 17.94% to $956718.0 in 2025, then increased by 10.95% to $1.1 million in 2026.
• Business Quant data shows RMTG's Cash & Equivalents at $1.1 million in Q1 2026, $956718.0 in Q4 2025, and $1.2 million in Q3 2025.